Product Description
Idarubicin hydrochloride 57852-57-0
AI Product Description
*The following content is generated by AI and is for reference only.
Idarubicin hydrochloride is a potent anthracycline antibiotic derived from daunorubicin, widely recognized for its significant efficacy in the treatment of acute myeloid leukemia (AML). Its chemical identity is defined by the molecular formula C27H29NO8·HCl and the CAS registry number 60020-34-6. This synthetic derivative features a unique 1-hydroxy group at position 5 of the aglycone ring, which enhances its lipophilicity compared to its parent compound. This structural modification allows idarubicin to penetrate cell membranes more effectively, leading to improved intracellular accumulation within leukemic cells and superior therapeutic outcomes in clinical settings.
The primary mechanism of action involves the intercalation of the drug between DNA base pairs, thereby inhibiting topoisomerase II. This interference disrupts DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells. Additionally, idarubicin generates free radicals that cause oxidative damage to cellular components, further contributing to its cytotoxic effects. Due to these properties, it is predominantly administered as a first-line therapy for adult patients with newly diagnosed AML, often in combination with cytarabine or other chemotherapeutic agents. It may also be utilized in salvage regimens for relapsed or refractory cases.
Despite its clinical utility, idarubicin hydrochloride presents a narrow therapeutic index and carries risks of severe adverse effects. The most critical concern is cumulative dose-dependent cardiotoxicity, which can manifest as congestive heart failure or irreversible myocardial damage. Other common side effects include profound myelosuppression, nausea, vomiting, alopecia, and mucositis. Because of these risks, strict monitoring of cardiac function and blood counts is mandatory during treatment protocols. Patients must be carefully selected based on their overall health status and prior exposure to other anthracyclines. As a prescription-only medication, it is supplied as a sterile lyophilized powder for intravenous reconstitution and administration under the supervision of specialized oncology professionals. Continuous research aims to optimize dosing strategies to maximize efficacy while minimizing long-term toxicity, ensuring safer management for leukemia patients worldwide.